Theravance Biopharma (TBPH) Tax Rate (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Tax Rate of 23.18% for Q1 2026, up 1923.0% year-over-year from 1.15% in Q1 2025, and down 48.63% quarter-over-quarter from 45.13% in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Tax Rate (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Tax Rate for 13 consecutive years, with 23.18% the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Rate rose 1923.0% year-over-year to 23.18%; the TTM figure through Mar 2026 stood at 29.24% (up 4988.0% YoY), while the FY2025 annual figure was 32.17%, up 5863.0% from the prior year.
- Tax Rate fell to 23.18% in Q1 2026 per TBPH's latest filing, from 45.13% in the prior quarter.
- Across five years, Tax Rate topped out at 225.13% in Q3 2025 and bottomed at 73.7% in Q4 2024.
- Historically, Tax Rate has averaged 10.08% across 5 years, with a median of 0.02% in 2022.
- Annual changes were most pronounced in 2024 — Tax Rate slumped 6798 bps — and 2025, when it soared 25145 bps.
- Theravance Biopharma's Tax Rate stood at 0.02% in 2022, then tumbled by 27295 bps to 5.72% in 2023, then plunged by 1188 bps to 73.7% in 2024, then surged by 161 bps to 45.13% in 2025, then plunged by 49 bps to 23.18% in 2026.
- Business Quant data shows TBPH's Tax Rate at 23.18% in Q1 2026, 45.13% in Q4 2025, and 225.13% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Tax Rate (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.98% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 15.11% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -10.89% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 24.15% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 7.49% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.71% |
| 10 | Theravance Biopharma | 882.99 Mn | 495.33 Mn | - | -23.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.11% |
| Mar 31, 2026 | 23.76% |
| Dec 31, 2025 | 32.25% |
| Sep 30, 2025 | 225.13% |
| Jun 30, 2025 | 25.09% |
| Mar 31, 2025 | 3.95% |
| Dec 31, 2024 | -129.29% |
| Sep 30, 2024 | -26.32% |
| Jun 30, 2024 | -8.59% |
| Mar 31, 2024 | -12.13% |
| Dec 31, 2023 | -69.66% |
| Sep 30, 2023 | -18.03% |
| Jun 30, 2023 | -10.28% |
| Mar 31, 2023 | 1.76% |
| Dec 31, 2022 | 1,255.43% |
| Sep 30, 2022 | 3.16% |
| Jun 30, 2022 | 0.02% |
| Mar 31, 2022 | -1.32% |
| Dec 31, 2021 | 0.35% |
| Sep 30, 2021 | 0.01% |